Abstract:BACKGROUND: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as indicators for pulmonary damage with clinical value in the diagnosis and prognosis of SSc-ILD.OBJECTIVES: To investigate the role of serum biomarkers (Krebs von den Lungen-6 KL-6, IL-18 and IL-18BP) as a potential biomarker reflecting the severity of SSc-ILD as assessed through high-resolution computed tomography (HRCT) and pulmonary function tests (PFT), including forced vital capacity (%FVC) and diffusing capacity of the lung for carbon monoxide (%DLCO).METHODS: A cross-sectional study including patients with SSc fulfilling the 2013 ACR/EULAR criteria was performed. Patients were classified according to disease duration and pulmonary involvement (presence of ILD). All SSc patients underwent chest HRCT scans and pulmonary function test at baseline. Serum concentration of KL-6, IL8 and IL18BP were determined using the quantitative ELISA technique, sandwich type (solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay), with kits from MyBiosource for KL-6 and from Invitrogen for IL18 and IL18BP. A semiquantitative grade of ILD extent was evaluated through HRCT scan (grade 1, 0-20%; grade 2, >20%). Extensive disease was defined as >20% lung involvement on HRCT, and FVC <70% predicted and limited lung involvement as ≤20% ILD involvement on HRCT, and an FVC ≥70% predicted.RESULTS: 74 patients were included, 27% were male. The mean age at diagnosis was 57.5±15 years and the mean time since diagnosis was 7.67±8 years. 28 patients had ILD (38%). 64% of patients had <20% ILD extent classified through HRCT scan. SSc-ILD patients had elevated serum KL-6 and IL-18 levels compared to patients without ILD (p=0.003 and p=0.04), and those findings were preserved after adjusting for age and sex. Negative correlation between KL-6 levels and%FVC (β=-0.25, p 0.037) and% DLCO (β=-0.28, p 0.02) and between IL-18 levels and%FVC (β=-0.38, p 0.001) and%DLCO (β=-0.27, p 0.03) were found. Serum KL-6 and IL-18 levels successfully differentiated grades 1 and 2 of the semiquantitative grades of ILD extent (p = 0.028 and p = 0.022). Semiquantitative grades of ILD on the HRCT scan were significantly proportional to the KL-6 (p = 0.01) and IL-18 (p = 0.03). A positive correlation between extensive lung disease and KL-6 (β=0.42, p = 0.007) but not with IL-18 was found.CONCLUSIONS: Serum KL-6 levels and IL-18 were increased in patients with SSc-ILD and showed a positive correlation with ILD severity as measured using a semiquantitative CT grading scale and negative correlation with PFT parameters. Serum KL-6 and IL-18 could be a clinically useful biomarker in screening and evaluating SSc-ILD.

The Detection and Measurement of Interleukin-6 in Venous and Capillary Blood Samples, and in Sweat Collected at Rest and During Exercise.

Development of Quantum Dot-Based Fluorescence Lateral Flow Immunoassay Strip for Rapid and Quantitative Detection of Serum Interleukin-6

Optical Detection of Interleukin-6 Using Liquid Janus Emulsions Using Hyperthermophilic Affinity Proteins

Microparticles in Human Perspiration as an Inflammatory Response Index

Plasma interleukin-6 concentration in Standardbred racehorses determined by means of a novel validated ELISA

Novel Biosensor for InterLeukin-6 Detection

The Development of an Isotope Dilution Mass Spectrometry Method for Interleukin-6 Quantification

Analytical and Clinical Validation of an Automated Microfluidic Interleukin-6 Immunoassay

A novel electrochemical IL-6 sensor based on Au nanoparticles-modified platinum carbon electrode

High levels of "complexed" interleukin-6 in human blood

Digital Sers Immunoassay of Interleukin-6 Based on Au@Ag-Au Nanotags

Study on Levels of Serum IL-6 and IL-6 Mrna Expression in Neonatal Sepsis and Septic Shock

Analytical evaluation of the automated interleukin-6 assay on the Roche cobas e602 analyzer

Peripheral blood IL-6 levels in systemic sclerosis patients: Correlation between IL-6 levels and clinical phenotypes

KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD)

Serum interleukin-6 in chronic obstructive pulmonary disease patients and its relation to severity and acute exacerbation

Recent Advances in Electrochemical and Optical Biosensors Designed for Detection of Interleukin 6

Hierarchical Au@Pt nanoparticle/amino benzoic acid polymer-based hybrid material for labeled and label-free detection of interleukin-6: a comparative assessment

AB1226 The diagnostic value of serum kl-6 in connective tissue disease associated interstitial lung disease

Diagnostic performance of specific biomarkers for interstitial lung disease: a single center study

Exhaled breath condensate in ILD with ultrasensitive cytokine measurement: paving the way of a non-invasive investigational tool